

Chronic Kidney Disease (CKD) – Pipeline Insight, 2020

<https://marketpublishers.com/r/CA31E8C4CA95EN.html>

Date: September 2020

Pages: 104

Price: US\$ 2,500.00 (Single User License)

ID: CA31E8C4CA95EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Chronic Kidney Disease (CKD) – Pipeline Insight, 2020," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chronic Kidney Disease Understanding

Chronic Kidney Disease (CKD): Overview

CKD is a condition in which the kidneys are damaged and cannot filter blood as well as they should. Because of this, excess fluid and waste from blood remain in the body and may cause other health problems, such as heart disease and stroke. Some other health consequences of CKD include:

Anemia or low number of red blood cells

Increased occurrence of infections

Low calcium levels, high potassium levels, and high phosphorus levels in the

blood

Loss of appetite or eating less

Depression or lower quality of life

Symptoms

There are usually no symptoms of kidney disease in the early stages. It may only be diagnosed if you have a blood or urine test for another reason and the results show a possible problem with your kidneys. At a more advanced stage, symptoms can include:

tiredness

swollen ankles, feet or hands

shortness of breath

feeling sick

blood in your pee (urine)

Diagnosis

Blood tests: Kidney function tests look for the level of waste products, such as creatinine and urea, in blood.

Urine tests: Analyzing a sample of urine may reveal abnormalities that point to chronic kidney failure and help identify the cause of chronic kidney disease.

Imaging tests: Doctor may use ultrasound to assess kidneys' structure and size. Other imaging tests may be used in some cases.

Removing a sample of kidney tissue for testing: Doctor may recommend a kidney biopsy to remove a sample of kidney tissue. Kidney biopsy is often done with local anesthesia using a long, thin needle that's inserted through your skin and into your kidney. The biopsy sample is sent to a lab for testing to help

determine what's causing kidney problem.

Treatment

There is no cure for chronic kidney failure. However, there are measures can be taken to slow its progression. Calcium and vitamin D supplements help to protect your bones. Antihistamines can relieve the symptom of itchy skin. Antiemetics can help with nausea. Dietary changes might also be necessary.

Chronic Kidney Disease Emerging Drugs Chapters

This segment of the Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Kidney Disease Emerging Drugs

AZD5718: AstraZeneca

AstraZeneca is conducting a study to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease. The study will be conducted in approximately 118 study centers across 12 countries. The overall study period will be around 28 weeks. Approximately 632 participants comprising of 67% diabetic kidney disease (DKD) and 33% non-DKD participants will be enrolled.

DDO-3055: Jiangsu HengRui Medicine Co., Ltd.

Jiangsu HengRui Medicine is conducting a randomized, double-blind, dose-escalating, placebo controlled, phase I study to evaluate the safety and pharmacokinetics and pharmacodynamics of DDO-3055 in healthy volunteers and patients with Chronic Kidney Disease. This is a randomized, double-blind, dose-escalating, placebo controlled, Phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of DDO-3055 in healthy volunteers and patients with chronic kidney

disease. 48 healthy volunteers will be enrolled in Part A, and 18 patients with chronic kidney disease will be enrolled in Part B.

Further product details are provided in the report

Chronic Kidney Disease: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Kidney Disease

There are approx. 50+ key companies which are developing the therapies for Chronic Kidney Disease. The companies which have their Chronic Kidney Disease drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, AstraZeneca, UnicoCell Biomed, Jiangsu Hansoh Pharmaceutical, Bio Sidus, Keryx Biopharmaceuticals, AMAG Pharmaceuticals, inRegen, AbbVie etc.

Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Proteins and peptides

Polymers

Diamines

Chlorinated hydrocarbons

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Kidney Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Kidney Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Kidney

Disease drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Kidney Disease.

August 2020: DAPA-CKD trial meets primary endpoint in patients with chronic kidney disease. Dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalisation and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes. That's the main result of the DAPA-CKD trial presented in a Hot Line session today at ESC Congress 2020.

Chronic Kidney Disease Report Insights

Chronic Kidney Disease Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Chronic Kidney Disease Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chronic Kidney Disease drugs?

How many Chronic Kidney Disease drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chronic Kidney Disease and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AdAlta Ltd

Allena Pharmaceuticals Inc

apceth Biopharma GmbH

Arch Biopartners Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

BiOrion Technologies BV

Boehringer Ingelheim GmbH

Boryung Pharmaceutical Co Ltd

Celgene Corp

Certa Therapeutics Pty Ltd

Conatus Pharmaceuticals Inc

Corvidia Therapeutics Inc

DiaMedica Therapeutics Inc

Dimerix Bioscience Pty Ltd

DiscoveryBiomed Inc

DURECT Corp

Epigen Biosciences Inc

Galectin Therapeutics Inc

GenKyoTex SA

GNI Group Ltd

iBio Inc

IC-MedTech Inc

Ipsen SA

Isarna Therapeutics GmbH

KBP BioSciences Co Ltd

Kidney Fibrosis

Klotho Therapeutics Inc

Les Laboratoires Servier SAS

ManRos Therapeutics

Mironid Ltd

NovaTarg Therapeutics Inc

Novo Nordisk AS

OPKO Health Inc

Opsidio LLC

Otsuka Holdings Co Ltd

Pharmaxis Ltd

Q BioMed Inc

Redx Pharma Plc

Regulus Therapeutics Inc

Resverlogix Corp

Sanwa Kagaku Kenkyusho Co Ltd

Sarfez Pharmaceuticals Inc

Scholar Rock Inc

Sirnaomics Inc

Sphaera Pharma Pte Ltd

Symic Biomedical Inc

Taisho Pharmaceutical Holdings Co Ltd

Theravance Biopharma Inc

Unity Biotechnology Inc

Vascular Biogenics Ltd

Vascular BioSciences

VESSL Therapeutics Ltd

Vicore Pharma AB

Key Products

AZD5718

MEDI8367

efepoetin alfa

Verinurad

Empagliflozin

DDO-3055

KBP-5074

Doxercalciferol

TRC101

Pegol-Sihematide

Contents

Introduction

Executive Summary

Chronic Kidney Disease: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Chronic Kidney Disease – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Chronic Kidney Disease companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Chronic Kidney Disease Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Pegol-Sihematide: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

AZD5718: AstraZeneca

Product Description

Research and Development

Product Development Activities

KBP-5074: KBP Biosciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Chronic Kidney Disease Key Companies

Chronic Kidney Disease Key Products

Chronic Kidney Disease- Unmet Needs

Chronic Kidney Disease- Market Drivers and Barriers

Chronic Kidney Disease- Future Perspectives and Conclusion

Chronic Kidney Disease Analyst Views

Chronic Kidney Disease Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Chronic Kidney Disease
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Chronic Kidney Disease
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Chronic Kidney Disease (CKD) – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/CA31E8C4CA95EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA31E8C4CA95EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970